Dysregulated Leukotriene Metabolism in Patients with COVID-19

Creative Commons License

DOĞAN H. O., BUDAK M., Doğan K., Zararsız G. E., YERLİTAŞ S. İ., BOLAT S., ...Daha Fazla

Japanese journal of infectious diseases, cilt.77, sa.3, ss.129-136, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 3
  • Basım Tarihi: 2024
  • Doi Numarası: 10.7883/yoken.jjid.2023.211
  • Dergi Adı: Japanese journal of infectious diseases
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.129-136
  • Anahtar Kelimeler: 5-lipooxygenase, 5-LO activating protein, COVID-19, cysteinyl leukotriene, cysteinyl leukotriene receptor
  • Atatürk Üniversitesi Adresli: Evet

Özet

This study aimed to examine the leukotriene metabolism during COVID-19. In total, 180 participants were included in this study, of which 60 were healthy controls, 60 required intensive care units (ICU), and 60 did not require intensive care (non-ICU). The serum levels of 5-lipoxygenase (5-LO), 5-LO activating protein (ALOX5AP), and cysteinyl leukotriene (CYSLT) were measured, and the mRNA expression levels of 5-LO, ALOX5AP, and cysteinyl leukotriene receptor 1 (CYSLTR1) were investigated. Compared with the control group, both the non-ICU and ICU groups had lower levels of 5-LO and mRNA expression. ICU patients had lower levels of 5-LO and mRNA expression than non-ICU patients. CYSLTR1 mRNA expression was highest in the ICU group, followed by the non-ICU group, and healthy controls had the lowest mRNA expression levels. CYSLT levels were higher in the control group than in the non-ICU and ICU groups. CYSLTR1 expression was higher in patients than in controls; therefore, selective leukotriene receptor blockers can be used as treatment options. CYSLTR1 expression was higher in the ICU group than in the non-ICU group. Furthermore, CYSLTR1 mRNA expression may be a promising biomarker of COVID-19 severity.